Biocodex is a French family-owned pharmaceutical company headquartered in Gentilly, near Paris, France. The company was founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745, discovered in 1923. Since then, Biocodex has evolved from a pioneer to a major international player in the microbiota realm. Meanwhile, Biocodex’s R&D center has focused on the central nervous system, developing an orphan drug, DIACOMIT®. At the end of 2019, Biocodex pursued its diversification with the acquisition of Laboratoires Iprad, a pharmaceutical company specialized in woman’s health. Biocodex focuses its business on three main areas: - Microbiota to educate the general public and healthcare professionals on the growing importance of microbiota, advance scientific breakthroughs in microbiota by funding academic research, provide solutions for preserving microbiota health with its unique probiotic drug Saccharomyces boulardii CNCM I-745, innovate with its Symbiosys range and make early-stage investments in start-up companies - Orphan diseases for patients with severe orphan pathologies around the world, such as DIACOMIT®, which is indicated for the treatment of Dravet syndrome, a rare and very severe form of epilepsy in children - Women’s health with the Saforelle brand for women of all ages. With 1,626 employees, Biocodex generated net revenues of €418 million in 2021, including 40% in France and 60% internationally. The group is present in 124 countries through wholly-owned subsidiaries in 20 countries and a network of distributors worldwide.